Focusing on biophysical sciences


NovAliX strongly believes in biophysical sciences for investigation and characterization of small molecules and biologics and has continously invested in the development of corresponding capabilities to support progress in research and development programs.



X-Ray Cristallography
an image

NovAliX structural biology group is a world leader in the nuclear hormone receptors field and have extended its expertise to numerous protein classes including kinases, proteases, phosphotases, PDEs or protein/antibody complexes by using an efficient gene-to-structure platform combined with strong know-how in crystallography.

NMR
an image NovAliX NMR group provides expertise and proprietary solutions leveraging the three major NMR technologies
  • Solution-phase for screening and complex mixture analysis (DOSY experiment)
  • Solid-state for polymorphism and formulation studies
  • HR-MAS for soft-solid, emulsion and gel characterization
Native MS
an image

NovAliX has developed a unique and innovative platform using supramolecular mass spectrometry for compound screening and binding characterization. This screening technology has emerged as a novel and efficient technique for delivering high-content information on compound-protein interactions.

Vivat et al., Future Med. Chem., Jan 2010 (2), 1, 35-50.

SPR
an image

The Graffinity technology is a unique platform which includes chemical microarrays with a proprietary SPR label-free imaging system for characterization of protein-ligand as well as protein--protein interactions.

It's high sensitivity and throughput makes it the technology of choice for fragment screening.


Neumann et al., Curr Top Med Chem. 2007;7(16):1630-42.





  Return to top

Meet us
Novalix will be exhibiting at Molecular Med Tri-Con 2012 in San Francisco, USA (21th-23th February). Visit us at booth 223.

Novalix be present at Biopartnering North-America 2012 in Vancouver, Canada (26th-28th February). Contact us for the organization of a meeting.

Highlight
January 12, 2011

NovAliX SAS announced today that it has entered into a multi-target integrated drug discovery collaboration with Teijin Pharma Limited of Tokyo, Japan.
Read more...


September 13, 2011

NovAliX to collaborate with Fondation Jérôme Lejeune on Down syndrome (trisomy 21).
Read more...


August 29, 2011

NovAliX and Galapagos collaborate in osteoarthritis discovery research program.
Read more...


March 30, 2011

Graffinity Pharmaceuticals GmbH, a member of the NovAliX group of companies (www.novalix.com), announced today that it has entered into a research collaboration with Osaka, Japan based Shionogi & Co., Ltd.
Read more...


Contact Information
an image
NovAliX
BioParc, bld Sebastien Brant,
67400 Illkirch
Email: info@novalix-pharma.com

Phone: +33 (0) 368 330 200
Fax: +33 (0) 368 330 201